¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Hodgkin's disease, mixed cellularity type"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
  • hyperbaric disease
    °í¾Ðº´
  • iatrogenic disease
    ÀÇÀκ´, ÀÇ¿øº´
  • iron-storage disease
    öÃàÀûÁúȯ
  • ischemic bowel disease
    ÇãÇ÷Àå¿°, ÇãÇ÷âÀÚ¿°
  • ischemic heart disease
    ÇãÇ÷½ÉÀ庴
  • immune deposit disease
    ¸é¿ªÄ§Âøº´
  • immune-complex disease
    ¸é¿ªº¹ÇÕüº´
  • immunodeficiency disease
    ¸é¿ª°áÇ̺´
  • immunological disease
    ¸é¿ªº´, ¸é¿ªÁúȯ
  • immunoproliferative disease
    ¸é¿ª¼¼Æ÷Áõ½Äº´, ¸é¿ªÁõ½ÄÁúȯ
  • imported disease
    ¼öÀÔº´
  • inclusion disease
    Æ÷ÇÔüº´, ºÀÀÔüº´
  • industrial disease
    »ê¾÷º´
  • infectious disease
    °¨¿°º´
  • inflammatory bowel disease
    ¿°ÁõâÀÚÁúȯ, ¿°Áõ¼ºÀåÁúȯ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
  • holoendemic disease
    ¼Ò¾ÆÇ³Å亴
  • hookworm disease
    ±¸Ã溴
  • hunger disease
    ±â¾Æº´
  • hyaline membrane disease
    À¯¸®Áú¸·º´
  • hydatid disease
    Æ÷Ãæº´
  • hyperbaric disease
    °í¾Ðº´
  • hyperendemic disease
    °ú´ÙºóµµÇ³Å亴
  • hypertensive disease
    °íÇ÷¾ÐÁúȯ
  • hypertensive heart disease
    °íÇ÷¾Ð½ÉÀ庴, °íÇ÷¾Ð½ÉÀåÁúȯ
  • hypertensive vascular disease
    °íÇ÷¾ÐÇ÷°üº´
  • iatrogenic disease
    ¿øÀÎºÒ¸íº´
  • idiopathic disease
    Ư¹ßº´, Àڹߺ´
  • immune deposit disease
    ¸é¿ªÄ§Âøº´
  • immune-complex disease
    ¸é¿ªº¹ÇÕüº´
  • immunodeficiency disease
    ¸é¿ª°áÇ̺´
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
  • Refsums disease
    ·¹ÇÁ¼û º´
  • Ritter disease
    ¸®ÅÍ º´
  • Rombergs disease = Romberg syndrome
    ·Òº£¸£Å©º´
  • Schilder s disease
    ½Ç´õº´.
  • Sheehans disease
    ½ÃÇѺ´
  • Sj?rens disease
    ¼î±×·»º´, ¼î±×·»ÁõÈıº
  • Stargardts disease=>fundus flavimaculatus
    ½ºÅ¸°¡¸£Æ®º´
  • Stills disease
    ½ºÆ¿ º´
  • Takahara disease
    ´ÙÄ«Ç϶óº´
  • Takayasu disease
    Ÿī¾ß¼öº´
  • Theilers disease
    ŸÀÏ·¯¸¶¿ì½º Ư¹ß¼º ³úô¼ö¿°
  • Thornwaldts disease
    Àεγ¶¿°
  • Tietzes disease
    ƼÂź´.
  • VDRL test= venereal disease research laboratory test
    ¼ºº´¿¬±¸¼Ò½ÄÅ×½ºÆ®.
  • VDRL test= venereal disease research laboratory test
    ¼ºº´¿¬±¸¼Ò½ÄÅ×½ºÆ®.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
  • linear array type
    ¼±Çü ¹è¿­½Ä (àÊû¡ ÛÕÖªãÒ)
  • linear type constitution
    ¼±Ã¼Çü.
  • lymphatic type
    ¸²ÇÁÇü(¡­úþ).
  • mating type
    ±³¹èÇü
  • men type
    MEN Çü(¡­ û¡)
  • meningeal type
    ¼ö¸·Çü(âÐØ¯úþ).
  • metaphyseal dysostosis dominant type
    °ñ °£´Ü¼º À̰ñÁõ ¿ì¼ºÇü(ÍéÊÏÓ®àõì¶ÍéñøéÐàõúþ).
  • metaplastic bone (type)
    È­»ý°ñ(Çü)(ûùßæÍéû¡).
  • mobile type diagnostic X ray apparatus
    À̵¿Çü Áø´Ü X¼± ÀåÄ¡
  • monocytic type
    ´ÜÇÙ±¸Çü(¡­û¡).
  • monocytic type
    ´ÜÇÙ±¸Çü(Ó¤ú·Ï¹û¡)
  • monocytic type
    ´ÜÇÙ±¸Çü(?Ì´).
  • muscular type of artery
    ±ÙÀ°Çüµ¿¸Æ
  • muscular type of lymphatic vessel
    ±ÙÀ°Çü¸²ÇÁ°ü
  • muscular type of vein
    ±ÙÀ°ÇüÁ¤¸Æ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 16
MCN maternal child nursing; minimal change nephropathy; mixed cell nodular [lymphoma]
MECG mixed essential cryoglobulinemia
MFO medium frequency oscillator; mixed function oxidase
MGD maximal glucose disposal; mixed gonadal dysgenesis
MHA major histocompatibility antigen; May-Hegglin anomaly; Mental Health Association; methemalbumin; mic...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 16
11 beta-HSD2 11 beta-Hydroxysteroid dehydrogenase type 2
5-HT3 5-hydroxytryptamine type 3
ANP A type natriuretic peptide
AT1 A-II type 1
AT(1) ANG II type 1
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • hyaline membrane disease
    À¯¸®Áú¸·º´
    ¹Ì¼÷¾Æ¿¡¼­ Ãâ»ý Á÷ÈÄ ¹ß»ýÇÏ´Â °¡Àå ÈçÇÑ Áúº´ Áß Çϳª·Î¼­ ½Å»ý¾Æ »ç¸ÁÀÇ Áß¿ä ¿øÀÎÁß ÇϳªÀÌ´Ù.
  • hydatid disease
    Æ÷ÃæÁõ, Æ÷Ãæº´
  • hypokinetic disease
    µµÈ¸º´, ¿îµ¿ ºÎÁ· º´
  • idiopathic disease
    Ư¹ßº´
    ´Ù¸¥ ÁúȯÀÇ °á°ú·Î ¹ß»ýÇÏÁö ¾Ê´Â Áúº´À¸·Î¼­, ¿øÀÎÀº ºÒ¸íÀÌ´Ù.
  • immune deficiency disease
    ¸é¿ª °áÇÌ Áúȯ, ¸é¿ª °áÇ̺´
    ¸é¿ª °èÅëÀ» ±¸¼ºÇÏ´Â ¿ä¼ÒÀÇ ±â´É Àå¾Ö¿¡ ÀÇÇÏ¿© ÃÊ·¡µÇ´Â Áúȯ ±º.
  • immunologic disease
    ¸é¿ª Áúȯ, ¸é¿ªÇÐÀû Áúȯ
  • inclusion body disease
    ºÀÀÔü º´
    ¼¼Æ÷ ºÀÀÔü°¡ ³ªÅ¸³ª´Â Áúȯ. ƯÈ÷ ¹ÙÀÌ·¯½º º´¿¡¼­ ÈçÇÏ´Ù.
  • infectious disease
    °¨¿° Áúȯ, °¨¿°¼º Áúȯ, °¨¿°º´, Àü¿°º´
    °¨¿°À» ÀÏÀ¸Å°´Â ¼÷ÁÖ´Â Á¦°¢±â º´¿øÃ¼¿¡ ´ëÇØ¼­ ƯÀ¯ÇÑ ¹ÝÀÀÀ» ³ªÅ¸³»°í ¹ÝÀÀÀÇ º´ÀûÀÎ Á¤µµ¿¡ ´ÞÇØ ÀÓ»ó Áõ»óÀÌ ³ªÅ¸³­ ÁúȯÀ» ¸»ÇÑ´Ù. °¨¿°À» ÀÏÀ¸Äѵµ ¹Ýµå½Ã ¹ßº´ÇÑ´Ù°í´Â ÇÒ ¼ö ¾ø°í ±× º´¿øÃ¼ÀÇ Á¾·ù, º´¿øÃ¼ÀÇ °¨¿°·Â¿¡ °üÇÑ ÀÎÀÚ¿Í °¨¿°ÇÑ »ýüÀÇ °¨¼ö¼º, ¸é¿ª, ±× ¹ÛÀÇ ÀúÇ׷¿¡ °üÇÑ ÀÎÀÚ¿ÍÀÇ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ¼­ °áÁ¤µÈ´Ù.
  • ischemic heart disease
    ÇãÇ÷¼º ½É Áúȯ
  • Jadassohn's disease
    ¾ß´ÙÁ¸ º´
    ¹Ý»ó ±¸Áø»ó È«ÇÇÁõ.
  • Jod-Basedow disease
    Jod-Basedow Áúȯ
    ¿ä¿Àµå À¯¹ß¼ºÀÇ °©»ó¼± ±â´É Ç×ÁøÁõ.
  • jumping disease
    ¹«µµº´
  • Kahler's disease
    Kahler º´
    ´Ù¹ß¼ºÀÇ °ñ¼öÁ¾À¸·Î ÀϹÝÀûÀÎ °ñ ¼¼Æ÷¿¡¼­ º¼ ¼ö ÀÖ´Â Á¾¾ç.
  • Kawasaki disease
    °¡¿Í»çŰ º´
    °©ÀÛ½º·± ¿­°ú Àü½Å¿¡ ¹ßÁøÀÌ ³ªÅ¸³ª´Â ¿øÀÎ ºÒ¸íÀÇ Áúȯ. 1967³â ÀϺ»¿¡¼­ óÀ½À¸·Î º¸°íµÈ µ¥¼­ ÀÌ·± º´¸íÀÌ ºÙ¾ú´Ù. È«¿ª, ¼ºÈ«¿­, dzÁø µî°ú ºñ½ÁÇÑ Áõ¼¼¸¦ º¸À̹ǷΠ°¨º°¿¡ À¯ÀÇÇØ¾ß ÇÑ´Ù. Áõ¼¼·Î´Â, ¨ç °í¿­ÀÌ 5ÀÏ ÀÌ»ó °è¼ÓµÈ´Ù. ¨è ´«ÀÌ ÃæÇ÷µÈ´Ù. ¨é ¼Õ¹Ù´Ú, ¹ß¹Ù´ÚÀÌ »¡°²°Ô ºÎ¾î¿À¸£¸é¼­ ²®ÁúÀÌ ¹þ°ÜÁø´Ù. ¨ê Àӯļ±ÀÌ º×´Â´Ù. ¨ë ÀÔ¼úÀÌ ºÓ¾îÁø´Ù. ¨ì Àü½Å ¹ßÁø Áõ¼¼ µîÀ» º¸À̴µ¥, ÀÌ °¡¿îµ¥ 5°¡Áö ÀÌ»óÀÇ Áõ¼¼¸¦ º¸À̸é ÀÌ º´À» ÀǽÉÇØ¾ß ÇÑ´Ù. ¹ÙÀÌ·¯½º °¨¿°¼³, Áß¼º ¼¼Á¦¼³, Ä­µð´Ù ¼¼±Õ¼³ µîÀÌ ¿øÀÎÀ̶ó´Â Çм³ÀÌ Á¦±âµÇ¾úÀ¸³ª È®½ÇÇÏ°Ô ¹àÇôÁöÁö ¾Ê°í ÀÖ´Ù. 90 % ÀÌ»óÀÌ 1~4¼¼ÀÇ ¿µ, À¯¾Æ±â¿¡ ¹ßº´Çϸç, ¿©¾Æº¸´Ù´Â ³²¾Æ¿¡°Ô ÁÖ·Î ¹ßº´ÇÑ´Ù. ¶ÇÇÑ ¹ßº´·üÀÌ ¼­¾çÀκ¸´Ù µ¿¾çÀο¡°Ô ³ô´Ù. ¿¹¹æ¹ýÀº ÇöÀç µû·Î ¾ø°í Áõ¼¼¸¦ º¸ÀÎ ÈÄ 2~3ÁÖ¸é ÀÚ¿¬ Ä¡À¯µÇ³ª ½ÉÀå ÇÕº´ÁõÀ» ÀÏÀ¸ÄÑ ±Þ»çÇÒ À§ÇèÀÌ ÀÖ´Â Áúº´À̱⵵ ÇÏ´Ù. µû¶ó¼­ Á¶±â¿¡ ¹ß°ßÇÏ¿© ÇÕº´ÁõÀ» ¿¹¹æÇÏ´Â °ÍÀÌ Áß¿äÇÏ´Ù. Çѱ¹¿¡¼­´Â 73³â óÀ½À¸·Î ¹ß°ßµÈ ÀÌ·¡ 91³â 1, 228¸íÀÌ ¹ßº´, º¸°íµÇ¾ú´Ù.
  • Kimura disease
    Ű¹«¶ó º´
    ûÀå³â±âÀÇ ¿©ÀÚ¿¡°Ô ÁÖ·Î ¹ß»ýµÇ´Â ¸Æ¶õ¼º Áõ½Ä¼º º´¼ÒÀÌ´Ù. µÎ°æºÎ ÇÇÇÏ Á¶Á÷À̳ª ±¸°­³» ¶Ç´Â »ó¼ø ³»Ãø¿¡¼­ Àß ¹ß»ýµÇ¸ç ÀÌÇϼ± ºÎÀ§¿¡¼­µµ ÀÚÁÖ º¸ÀδÙ. Á¶Á÷ÇÐÀûÀ¸·Î ÀÌÇü¼º Ç÷°ü ³»ÇÇ ¼¼Æ÷ÀÇ Áõ½Ä°ú ¸¸¼º ¿°Áõ ¼¼Æ÷ÀÇ Ä§À±, È£»ê±¸ÀÇ Ä§À±ÀÌ ÀÖ°í ½ÉÇϸé È£»ê±¸ ³ó¾çµµ Çü¼ºÇÏ¸ç ¸²ÇÁ Á¶Á÷ÀÇ Áõ»óÀ» º¸ÀδÙ. Ÿ¾×¼± Á¶Á÷Àº À§ÃàµÇ°í ÀÖ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
type III collagen Collagen characteristic of reticular fibres.
(05 Mar 2000)
type III familial hyperlipoproteinaemia Hyperlipoproteinaemia characterised by increased plasma levels of LDL, beta-lipoproteins, pre-beta-lipoproteins, cholesterol, phospholipids, and triglycerides; hypertriglyceridemia induced by a high carbohydrate diet, and glucose tolerance is abnormal; frequent eruptive xanthomas and atheromatosis, particularly coronary artery disease; biochemical defect lies in apolipoproteins; there are many varieties.
Synonym: carbohydrate-induced hyperlipaemia, dysbetalipoproteinaemia, familial hyperbetalipoproteinaemia and hyperprebetalipoproteinaemia, familial hypercholesterolaemia with hyperlipaemia.
(05 Mar 2000)
type III hyperlipoproteinaemia <biochemistry> An inherited disorder (gene defect) where both cholesterol and triglycerides are elevated in the same patient. This condition accelerates the effects of atherosclerosis and thus increases the risk of cardiovascular disease. Conditions such as hypothyroidism, obesity and diabetes enhances this risk.
Origin: Gr. Haima = blood
(27 Sep 1997)
type III hypersensitivity reaction An immunologic category of diseases evoked by the deposition of antigen-antibody or antigen-antibody-complement complexes on cell surfaces, with subsequent involvement of breakdown products of complement, platelets, and polymorphonuclear leukocytes, and development of vasculitis; nephritis is common. Arthus phenomenon and serum sickness are classic examples, but many other disorders, including most of the connective tissue disease's, may belong in this immunologic category; immune complex disease's can also occur during a variety of disease's of known aetiology, such as subacute bacterial endocarditis.
See: autoimmune disease.
Synonym: immune complex disorder, type III hypersensitivity reaction.
(05 Mar 2000)
type III mucopolysaccharidosis <syndrome> An error of the mucopolysaccharide metabolism, with excretion of large amounts of heparan sulfate in the urine and severe mental retardation with hepatomegaly; skeleton may be normal or may present mild changes similar to those in Hurler's syndrome; several different types (A, B, C, and D) have been identified according to the enzyme deficiency; autosomal recessive inheritance.
Synonym: type III mucopolysaccharidosis.
(05 Mar 2000)
type II interferon <chemical> The major interferon produced by mitogenically or antigenically stimulated lymphocytes. It is structurally different from type I interferon (interferon type I) and its major activity is immunoregulation. It has been implicated in the expression of class II histocompatibility antigens in cells that do not normally produce them, leading to autoimmune disease.
Pharmacological action: antineoplastic agent, antiviral agents.
Chemical name: Interferon-gamma (human lymphocyte protein moiety reduced)
(12 Dec 1998)
type II mortality <epidemiology> A mortality schedule in which all hosts are assumed to die at a constant rate. This constant rate is equal to the inverse of the life expectancy.
(05 Dec 1998)
type II mucopolysaccharidosis <syndrome> An error of mucopolysaccharide metabolism characterised by deficiency of iduronate sulfatase, with excretion of dermatan sulfate and heparan sulfate in the urine; clinically similar to Hurler's syndrome but distinguished by less severe skeletal changes, no corneal clouding, and X-linked recessive inheritance.
Synonym: type II mucopolysaccharidosis.
(05 Mar 2000)
type I interferon <chemical> Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (interferon-alpha and interferon-beta).
Pharmacological action: antineoplastic agent, antiviral agents.
(12 Dec 1998)
type I mortality <epidemiology> A mortality schedule in which all hosts are assumed to live for a fixed number of years equal to the life expectancy.
(05 Dec 1998)
type IS mucopolysaccharidosis <syndrome> A hereditary metabolic disorder caused by a recessive gene which results in a deficiency of the enzyme alpha-L-iduronidase, which breaks down dermatan sulphate and heparan sulphate, two types of mucopolysaccharides (complex carbohydrates). Consequently, the mucopolysaccharides accumulate in the cells of the body and cause damage.
Symptoms include skeletal deformities, mental retardation, coronary artery disease, deafness, and stiff joints, among other things. There are mild and severe forms of the syndrome, the severe form is called Hurler syndrome, the mild form is called Scheie Syndrome, and children with an intermediate form have Hurler-Scheie Syndrome. Patients with the mild form generally suffer little to no mental retardation and survive to adulthood. There is presently no cure. Scheie's Syndrome is one of a number of related rare genetic mucopolysaccharide disorders, the most common being Hunter syndrome.
(09 Oct 1997)
type IVA,B mucopolysaccharidosis <syndrome> An error of mucopolysaccharide metabolism with excretion of keratan sulfate in urine; characterised by severe skeletal defects with short stature, severe deformity of spine and thorax, long bones with irregular epiphyses but with shafts of normal length, enlarged joints, flaccid ligaments, and waddling gait; autosomal recessive inheritance; type IV A mucopolysaccharidosis is due to an absence of galactose-1-sulfatase, while type IV B is due to a deficiency of a beta-galactosidase.
Synonym: Brailsford-Morquio disease, Morquio's disease, Morquio-Ullrich disease, type IVA, B mucopolysaccharidosis.
(05 Mar 2000)
type IV acrocephalosyndactyly Acrocephalosyndactyly with pointed nose, hypertelorism, cleft palate, congenital heart disease and pseudohermaphroditism; contractures of elbows and knees; soft tissue syndactyly, absent first metatarsal and great toe. Autosomal recessive.
(05 Mar 2000)
type IV collagen A less distinctly fibrillar form of collagen characteristic of basement membranes.
(05 Mar 2000)
type IV familial hyperlipoproteinaemia Plasma levels of VLDL, pre-beta-lipoproteins and triglycerides are increased on a normal diet, but beta-lipoproteins, cholesterol, and phospholipids are normal; hypertriglyceridemia is induced by a high carbohydrate diet; may be accompanied by abnormal glucose tolerance and susceptibility to ischemic heart disease; probably autosomal recessive inheritance.
Synonym: carbohydrate-induced hyperlipaemia, familial hyperprebetalipoproteinaemia, familial hypertriglyceridemia.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 16
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 16
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 16
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 16
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 16
ÅëÇÕ°Ë»ö ¿Ï·á